Press Releases
May 09, 2024 » NeuroSigma Announces Acceptance into 2024 Cohort of the KidsX Accelerator Program
January 18, 2024 » NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD
November 07, 2023 » NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System
October 03, 2023 » NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
July 12, 2023 » NeuroSigma Establishes Singapore Subsidiary
March 01, 2023 » NeuroSigma Announces New Telehealth Option for Patients and Caregivers Interested in eTNS for Pediatric ADHD
January 31, 2023 » NeuroSigma Announces Strategic Digital Marketing Partnership with Data360
November 08, 2022 » NeuroSigma Announces that Enrollment Commences in Two Large, Double-Blind Trials of eTNS for Pediatric ADHD
September 27,2022 » NeuroSigma Announces Receipt of Permanent HCPCS Codes from CMS for Monarch eTNS System
June 14, 2022 » NeuroSigma Announces That a Team Led by UCLA Researchers Receives NIH Grant to Conduct a Multicenter Trial of eTNS for Pediatric ADHD
April 7, 2022 » NeuroSigma Announces King’s College London Team Receives MHRA Approval to Commence Largest Clinical Trial of eTNS for Pediatric ADHD to Date
February 22, 2022 » NeuroSigma Receives FDA Breakthrough Device Designation for Monarch eTNS System®
January 25, 2022 » Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction
January 11, 2022 » NeuroSigma Announces Promotion of Dr. Colin Kealey to President
December 8, 2021 » NeuroSigma Announces a $5 Million Equity Investment by KT Corporation
June 14, 2021 » KT and NeuroSigma Announce Strategic Digital Health Partnership
March 11, 2021 » NeuroSigma Continues to Build a Substantial Global Bioelectronics Patent Portfolio
January 22, 2021 » NeuroSigma Successfully Obtains HCPCS Codes from CMS for the Monarch eTNS System
December 17, 2020 » NeuroSigma's Monarch eTNS for Pediatric ADHD Featured in MD+DI's List of the 10 Wearable Medical Devices that Redefined Healthcare
October 21, 2020 » NeuroSigma Announces Publication of ADHD Clinical Trial Data That Provide Additional eTNS Mechanism of Action
June 24, 2020 » NeuroSigma Congratulates Spanish Team for their Results in Randomized Controlled Trial of eTNS in Drug Resistant Epilepsy
October 17, 2019 » Teijin and NeuroSigma Enter into Exclusive License Agreement
October 8, 2019 » NeuroSigma Announces Partnership with Quick Care Pharmacy for Sales and Distribution of the Monarch eTNS System in the US
April 23, 2019 » NeuroSigma Announces FDA Clearance of Monarch eTNS System as First Non-Drug Treatment for Pediatric ADHD
March 12, 2019 » First double-blind controlled trial of TNS shows reduced symptoms in some children with ADHD with minimal risk
October 30, 2017 » UCLA Team Reports Positive Topline Results from Double-Blind Trial of NeuroSigma's Non-Invasive eTNS System for Treatment of Pediatric ADHD
December 10, 2015 » Preliminary Results Utilizing NeuroSigma's Monarch eTNS System for the Treatment of Traumatic Brain Injury Presented at the North American Neuromodulation Society Annual Meeting
November 16, 2015 » NeuroSigma's Monarch eTNS System Receives CE Mark Approval for ADHD
May 4, 2015 » NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting
January 6, 2015 » FDA Grants NeuroSigma Humanitarian Use Device (HUD) Designation
January 5, 2015 » UCLA Launches Phase II Pediatric Clinical Trial for the Treatment of ADHD with NeuroSigma's eTNS System
November 19, 2014 » NeuroSigma Congratulates Brazilian Medical Team for Their Top-Line Results in Phase II Clinical Trial of eTNS for Treatment of Depression
November 17, 2014 » NeuroSigma Announces Top-Line Findings of UCLA Phase II Clinical Trial of eTNS for the Treatment of Depression
November 3, 2014 » NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS)
October 21, 2014 » NeuroSigma Receives Notice of Allowance of U.S. Patent Application
October 15, 2014 » NeuroSigma and the U.S. Veterans Administration (VA) Enter into Cooperative Research and Development Agreement (CRADA)
August 26, 2014 » NeuroSigma, Inc. Files Registration Statement for Proposed Initial Public Offering
August 25, 2014 » U.S. Army Funds Phase II Clinical Trial at UCLA for the Treatment of PTSD with the NeuroSigma eTNS System
July 22, 2014 » Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome
July 9, 2014 » NIH Funds Phase 2 Clinical Trial at UCLA for the Treatment of ADHD with NeuroSigma's eTNS System
July 8, 2014 » Advances in Trigeminal Nerve Stimulation Featured at European Congress on Epileptology in Stockholm, Sweden
June 3, 2014 » Leading UCLA Physician Dr. Ian Cook Joins NeuroSigma As Chief Medical Officer and Senior Vice President
March 28, 2014 » NeuroSigma Expands Its Management Team with Two Former Amgen Finance Executives
February 25, 2014 » David Hayes, Former Partner at O'Melveny & Myers LLP and Haynes and Boone LLP, Joins NeuroSigma As Chief Administrative Officer, General Counsel and Sr. Vice President
February 11, 2014 » Former Amgen Finance Executive Carl Adams Joins NeuroSigma As Vice President and Controller
January 27, 2014 » Former Allergan Marketing Executive Gregory F. Brooks Joins NeuroSigma As Senior VP and Chief Commercial Officer
January 21, 2014 » External Trigeminal Nerve Stimulation (eTNS) Presentations at the American Epilepsy Society Meeting
July 29, 2013 » NeuroSigma Announces FDA Approval to Commence Phase III Trial
June 21, 2013 » NeuroSigma Announces Debut of Its Monarch eTNS System in Canada
June 6, 2013 » NeuroSigma Launches Dedicated Website to Introduce Its Monarch eTNS System for Epilepsy and Depression
April 18, 2013 » Results of Pediatric Clinical Trial of External Trigeminal Nerve Stimulation for the Treatment of ADHD
March 25, 2013 » External Trigeminal Nerve Stimulation (eTNS) For Refractory Status Epilepticus
February 11th, 2013 » NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London
February 4th, 2013 » NeuroSigma Awarded Fast Track SBIR Grant by the NIH for Development of Implantable sTNS System for Drug Resistant Epilepsy
January 30th, 2013 » NeuroSigma Announces Publication of Randomized Controlled Trial of eTNS for Treatment of Drug Resistant Epilepsy in the Leading Journal, Neurology®
January 22nd, 2013 » NeuroSigma Announces Receipt of Notice of Allowance of U.S. Patent Application Related to External Trigeminal Nerve Stimulation (eTNS) for the Treatment of Neuropsychiatric Disorders
September 25th, 2012 » NeuroSigma's Monarch eTNS System to be Unveiled in London
September 5th, 2012 » NeuroSigma Receives CE Certification
July 2nd, 2012 » NeuroSigma Receives Global Quality Control Certification
May 16th, 2012 » NeuroSigma Subsidiary Acquires Thin-Film Nitinol Fabrication Patent Portfolio
April 9th, 2012 » NeuroSigma Awarded NIH Grant for Further Development of Its Thin-Film Nitinol Covered Neurovascular Stent
April 2nd, 2012 » UCLA Neurologist and Innovator of Trigeminal Nerve Stimulation Joins NeuroSigma
November 29th, 2011 » NeuroSigma to Exhibit at the 2011 American Epilepsy Society Annual Meeting and Introduce External Trigeminal Nerve Stimulation - the USB Port to the Brain™
October 24th, 2011 » NeuroSigma Funds First-Ever Pediatric Clinical Trial to Study Non-Invasive External Trigeminal Nerve Stimulation for the Treatment of ADHD
September 6th, 2011 » NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy
August 4th, 2011 » NeuroSigma Responds to Substantial Interest Generated by NPR Story on Promising Epilepsy Clinical Trial
July 18th, 2011 » NSVascular, Inc., a NeuroSigma Subsidiary, Signs an Exclusive License Covering UCLA's Thin-Film Nitonol (TFN) Stent Technology for Endovascular Applications
July 5th, 2011 » Potential Mechanism of Action Identified for the Treatment of Major Depression With Trigeminal Nerve Stimulation (TNS) - The USB Port to the Brain™
April 25th, 2011 » NeuroSigma Provides Update on Trigeminal Nerve Stimulation (TNS) - the USB Port to the Brain
April 4th, 2011 » NeuroSigma, Inc. Retains CCG Investor Relations
December 3rd, 2010 » Report Favorable Results of Pilot Feasibility Trial for Trigeminal Nerve Stimulation for Epilepsy
September 2nd, 2010 » Non-invasive therapy signficiantly improves depression, UCLA researchers say
